Basic Information
| LncRNA/CircRNA Name | MIR4435-2HG |
| Synonyms | AGD2, LINC00978, MIR4435-1HG, MORRBID, lncRNA-AWPPH |
| Region | GRCh38_2:111036776-111523376 |
| Ensemble | ENSG00000172965 |
| Refseq | NR_015395 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Western blot, other |
| Sample | OC tissues and cell lines (UWB1.289, UWB1.289+BRCA1), plasma |
| Expression Pattern | up-regulated |
| Function Description | Upregulation of MIR4435-2HG distinguished early stage (Stage I and II) OC patients from healthy controls. Correlation analysis showed that plasma levels of MIR4435-2HG and TGF-?1 were positively correlated only in OC patients. qPCR and western blot analysis results showed that MIR4435-2HG overexpression led to upregulation of TGF-?1 in OC cells, while TGF-?1 treatment did not significantly affect MIR4435-2HG expression. Transwell invasion and migration assays showed that MIR4435-2HG and TGF-?1 promoted the invasion and migration of OC cells while TGF-? inhibitor suppressed the invasion and migration of these cells. Further analysis of the Transwell invasion and migration assay results showed that TGF-? inhibitor reduced the effects of MIR4435-2HG overexpression. |
| Pubmed ID | 31435668 |
| Year | 2019 |
| Title | LncRNA MIR4435-2HG Is a Potential Early Diagnostic Marker for Ovarian Carcinoma |
External Links
| Links for MIR4435-2HG | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |